Table 1.

Baseline characteristics of patients with V600E versus V600K metastatic melanoma (BRAFi±MEKi cohort)

CharacteristicsV600E (n = 78)V600K (n = 15)P value
Age (years)
 Median56.558.00.418
Gender (N, %)0.5786
 Female33 (42%)5 (33%)
 Male45 (58%)10 (67%)
AJCC stagea (N, %)1
 IIIC–M1b19 (24%)3 (20%)
 M1c59 (76%)12 (80%)
LDH (N, %)0.3563
 Normal57 (73%)9 (60%)
 Elevated21 (27%)6 (40%)
ECOG (N, %)1
 047 (60%)9 (60%)
 ≥131 (40%)6 (40%)
Treatment (N, %)0.3162
BRAFi62 (80%)10 (67%)
BRAFi + MEKi16 (20%)5 (33%)
  • aAJCC v7 anatomic staging, excluding LDH and brain metastases.